FDA gives thumbs up to new glucose monitoring device

The FDA approves Dexcom's (DXCM -2%) G4 Platinum Professional CGM (continuous glucose monitoring) device that monitors glucose levels in real time.

The product consists of a medical clinic-owned CGM system and sensors. Patients are set up for a period of seven days during which real time data are collected and can be shared with the patient. On the basis of two calibrations from a blood glucose meter daily, the G4 provides continuous readings on the rate and direction of glucose change as frequently as every five minutes. Physicians can then adjust therapy more rapidly. The G4 can be customized for personal glucose targets/alerts and has an alarm feature to alert the patient if glucose levels drift out of range.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs